Arkolith/Insider Trading/KIN/Form 4

Zhan Hangjun

Chief Scientific OfficerKindred Biosciences, Inc. (KIN) · full profile →Form 4 · filed Aug 30, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
12
1 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)64K$9.25$595K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)84K$4.81$402K0
Aug 27, 2021Disposed to issuer(D)50K—$00
Aug 27, 2021Disposed to issuer(D)100K—$00
Aug 27, 2021Disposed to issuer(D)80K$0.50$40K0
Aug 27, 2021Disposed to issuer(D)50K$1.60$80K0
Aug 27, 2021Disposed to issuer(D)75K$2.85$214K0
Aug 27, 2021Disposed to issuer(D)15K$5.65$85K0
Aug 27, 2021Disposed to issuer(D)10K$6.00$60K0
Aug 27, 2021Disposed to issuer(D)8K$2.29$18K0
Aug 27, 2021Disposed to issuer(D)8K$0.08$6000
Aug 27, 2021Disposed to issuer(D)12K—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001250853-21-000089) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML